Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quarterlies round-up: Becton Dickinson and Conmed feel effects of litigation while Guidant regroups as DES sales bite

This article was originally published in Clinica

Executive Summary

While Baxter recorded a healthy 10% increase in second quarter revenues compared with the same period last year, its overall performance was offset by special charges related to the company's restructuring initiatives announced in January 2004. These initiatives include eliminating 8% of its current global workforce, or approximately 4,000 positions. Around 50% of these job cuts will be made in the US. The company also reduced its plasma production by a further 400,000 litres, or 13%, on an annual basis and additional plasma collection centres have been closed as part of the company's streamlining process. The implementation of these restructuring plans has led to a total after-tax charge of $394m in the second quarter, resulting in a $170m net loss for that period.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts